Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEC-C2B8 for early relapse childhood-onset nephrotic syndrome (JSKDC12)
jRCT2051240106Recruiting
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of rituximab in Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoint: Relapse-free period. Started Nov 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on jRCT2051240106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240106.